Table 2.
Factors | Women with AIAA (N = 543) N (%) | Unadjusted OR |
Model 1 (Demographics & Clinical) |
Model 2 (Model 1 + Genetics) |
|||
---|---|---|---|---|---|---|---|
OR (95% CI) | P-value | AOR (95% CI) | P-value | AOR (95% CI) | P-value | ||
Demographic and Clinical | |||||||
Education | |||||||
High school or less | 73 (13) | 1 | – | 1 | – | 1 | – |
Some college or above | 469 (87) | 1.65 (1.19–2.30) | 0.003 | 1.45 (1.03–2.05) | 0.035 | 1.49 (1.00–2.20) | 0.047 |
Reasons for menopause | |||||||
Natural | 290 (54) | 1 | – | 1 | – | 1 | – |
Induced | 251 (46) | 1.49 (1.16–1.91) | 0.002 | 1.26 (0.95–1.66) | 0.11 | 1.20 (0.88–1.64) | 0.24 |
Years since LMP | |||||||
>10 years | 245 (46) | 1 | – | 1 | – | 1 | – |
5–10 years | 150 (28) | 1.78 (1.32–2.41) | <0.001 | 1.56 (1.13–2.14) | 0.006 | 1.55 (1.09–2.22) | 0.015 |
<5 years | 142 (26) | 2.38 (1.72–3.29) | <0.001 | 1.88 (1.31–2.70) | 0.001 | 1.78 (1.18–2.67) | 0.006 |
Chemotherapy | |||||||
No | 225 (41) | 1 | – | 1 | – | 1 | – |
Yes | 318 (59) | 1.57 (1.23–2.00) | <0.001 | 1.30 (0.99–1.70) | 0.06 | 1.38 (1.02–1.88) | 0.038 |
Aromatase inhibitors (AI) | |||||||
Anastrozole (Arimidex) | 421 (78) | 1 | – | 1 | – | 1 | – |
Exemestane (Aromasin) | 46 (9) | 1.70 (1.03–2.83) | 0.039 | 1.58 (0.92–2.69) | 0.10 | 1.28 (0.72–2.25) | 0.40 |
Letrozole (Femara) | 72 (13) | 0.87 (0.61–1.23) | 0.42 | 0.86 (0.59–1.26) | 0.44 | 0.82 (0.53–1.27) | 0.38 |
Years since start of AI | |||||||
>3 years | 121 (22) | 1 | – | 1 | – | 1 | – |
1–3 years | 264 (49) | 1.36 (1.01–1.84) | 0.040 | 1.32 (0.96–1.82) | 0.09 | 1.26 (0.89–1.78) | 0.20 |
<1 year | 158 (29) | 1.63 (1.17–2.29) | 0.004 | 1.68 (1.17–2.42) | 0.005 | 1.61 (1.08–2.40) | 0.019 |
Genetic SNP(s) | |||||||
rs11648233 | |||||||
C/C | 67 (15) | 1 | – | - | - | 1 | – |
C/A or A/A | 372 (85) | 2.03 (1.41–2.91) | <0.001 | - | - | 2.21 (1.55–3.16) | <0.001 |
Abbreviations: AIAA, aromatase inhibitor-associated arthralgia; OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; LMP, last menstrual period; SNP, single nucleotide polymorphism. Note: The bold and italicized text indicates a statistically significant P-value of <0.05.